BioSpace News Archive

Voyager Therapeutics, Inc. has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager.

PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington’s disease at study sites globally.

Berkeley Lights, Inc., a leader in digital cell biology, announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022.

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2022 financial and operating results after the market closes on Wednesday, November 2, 2022, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

NANOBIOTIX announced execution of a final agreement with the European Investment Bank to re-align approximately €30.7 million in outstanding debt obligations with the Company’s expected development and commercialization timelines.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2022 after the close of trading on Tuesday, November 8, 2022.

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter earnings release after the market closes on Tuesday, November 8, 2022.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the 7D FLASH™ Navigation System Percutaneous Spine Module.

Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2022 financial results will be released on Tuesday, November 1, 2022 after the markets close.